BioGaia AB is a Swedish biotechnology company specializing in probiotics and microbiome-based products. The company develops and markets evidence-based dietary supplements and medical nutrition solutions for gastrointestinal, oral, and immune health, built primarily around proprietary strains of Limosilactobacillus reuteri. Its portfolio includes finished formulations such as drops, tablets, and lozenges supplied to pediatric and adult markets.
BioGaia operates a research-driven model with strain-specific clinical studies, rigorous quality control, and established collaborations for production and distribution in global healthcare and retail channels. Headquartered in Stockholm, Sweden, and listed on Nasdaq Stockholm, the company focuses on strain selection, formulation stability, and regulatory compliance to bring probiotic products from R&D to market.